FDA Approval Alert: The Need-to-Know | Momelotinib for Myelofibrosis With Anemia

In September 2023, momelotinib was approved for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary and secondary myelofibrosis, who are experiencing anemia.

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.
CHMP Shares Positive Opinion of Momelotinib for Myelofibrosis/Anemia
Article
Nov 13, 2023 7:00 PM
If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.
Momelotinib Will ‘Make an Immediate Impact’ in Myelofibrosis With Anemia
Momelotinib Will ‘Make an Immediate Impact’ in Myelofibrosis With Anemia
Video
Sep 15, 2023 9:12 PM
With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.
Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.
Momelotinib Receives FDA Approval for Myelofibrosis With Anemia
Article
Sep 15, 2023 8:39 PM
Patients with myelofibrosis and anemia can now receive treatment with momelotinib following the agent’s approval by the FDA based on results from the phase 3 MOMENTUM trial.
Momelotinib Use in the MOMENTUM Trial
Momelotinib Use in the MOMENTUM Trial
Article
May 15, 2023 2:00 PM
Lead study author Ruben Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.